Trials / Completed
CompletedNCT03964207
A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
A Randomized, Open-label, Two-way Crossover Study to Compare Patient Acceptability/Preference of Tiotropium Respimat® With Tiotropium Handihaler® in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to investigate the patient acceptability/preference of Respimat® compared with Handihaler® in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) to demonstrate the superiority of Respimat®.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tiotropium Respimat® (T1) | inhalation solution |
| DRUG | Tiotropium Handihaler® (T2) | Inhalation Powder |
Timeline
- Start date
- 2019-11-25
- Primary completion
- 2021-10-19
- Completion
- 2021-11-16
- First posted
- 2019-05-28
- Last updated
- 2023-10-13
- Results posted
- 2023-10-13
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03964207. Inclusion in this directory is not an endorsement.